IP Library Patent Application 19421869
Patent Application
App. No. 19/421,869

COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/421,869
Abstract

The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.

Claims (53)

1 . A composition comprising a mixture of isomerically-purified hydroxypropyl β-cyclodextrin molecules comprising:

about 6% to about 12% β-cyclodextrin substituted with eight hydroxypropyl groups (“DS-8”);

about 18% to about 24% β-cyclodextrin substituted with nine hydroxypropyl groups (“DS-9”);

about 24% to about 30% β-cyclodextrin substituted with ten hydroxypropyl groups (“DS-10”);

about 10% to about 16% β-cyclodextrin substituted with eleven hydroxypropyl groups (“DS-11”);

about 4% to about 10% β-cyclodextrin substituted with thirteen hydroxypropyl groups (“DS-13”); and

about 0% to about 6% β-cyclodextrin substituted with fourteen hydroxypropyl groups (“DS-14”).

2 . The composition of claim 1 , wherein the mixture further comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”).

3 . The composition of claim 1 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”).

4 . The composition of claim 1 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with three hydroxypropyl groups (“DS-3”).

5 . The composition of claim 1 , wherein the mixture further comprises less than 0.05% unsubstituted beta-cyclodextrin (“DS-0”) and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group (“DS-1f”).

6 . The composition of claim 1 , wherein the composition further comprises no more than 10 ppb of propylene glycol as measured by HPLC.

7 . The composition of claim 1 , wherein the composition comprises no more than 1 ppm propylene oxide.

8 . The composition of claim 1 , wherein the composition comprises between 0 and 10 ppm chloride.

9 . The composition of claim 1 , wherein at least 50% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecules are located at the 2-O-position of the hydroxypropyl-β-cyclodextrin molecules.

10 . The composition of claim 1 , wherein 0% to 20% of the hydroxypropyl-β-cyclodextrin subunits are substituted at the 6-O-position.

11 . A composition comprising a mixture of isomerically-purified hydroxypropyl β-cyclodextrin molecules comprising:

β-cyclodextrin substituted with seven hydroxypropyl groups (“DS-7”);

β-cyclodextrin substituted with eight hydroxypropyl groups (“DS-8”);

β-cyclodextrin substituted with nine hydroxypropyl groups (“DS-9”);

β-cyclodextrin substituted with ten hydroxypropyl groups (“DS-10”);

β-cyclodextrin substituted with eleven hydroxypropyl groups (“DS-11”);

β-cyclodextrin substituted with thirteen hydroxypropyl groups (“DS-13”); and

β-cyclodextrin substituted with fourteen hydroxypropyl groups (“DS-14”),

wherein the mixture of isomerically-purified hydroxypropyl β-cyclodextrin molecules has an average degree of substitution of about 9 to about 10.

12 . The composition of claim 11 , wherein the mixture further comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”).

13 . The composition of claim 11 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”).

14 . The composition of claim 11 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with three hydroxypropyl groups (“DS-3”).

15 . The composition of claim 11 , wherein the mixture further comprises less than 0.05% unsubstituted beta-cyclodextrin (“DS-0”) and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group (“DS-1”).

16 . The composition of claim 11 , wherein the composition further comprises no more than 10 ppb of propylene glycol as measured by HPLC.

17 . The composition of claim 11 , wherein the composition comprises no more than 1 ppm propylene oxide.

18 . The composition of claim 11 , wherein the composition comprises between 0 and 10 ppm chloride.

19 . The composition of claim 11 , wherein at least 50% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecules are located at the 2-O-position of the hydroxypropyl-β-cyclodextrin molecules.

20 . The composition of claim 11 , wherein 0% to 20% of the hydroxypropyl-β-cyclodextrin subunits are substituted at the 6-O-position.

21 . A composition comprising a mixture of isomerically-purified hydroxypropyl β-cyclodextrin molecules comprising:

β-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”);

β-cyclodextrin substituted with seven hydroxypropyl groups (“DS-7”);

β-cyclodextrin substituted with eight hydroxypropyl groups (“DS-8”);

β-cyclodextrin substituted with nine hydroxypropyl groups (“DS-9”);

β-cyclodextrin substituted with ten hydroxypropyl groups (“DS-10”);

β-cyclodextrin substituted with eleven hydroxypropyl groups (“DS-11”);

β-cyclodextrin substituted with thirteen hydroxypropyl groups (“DS-13”); and

β-cyclodextrin substituted with fourteen hydroxypropyl groups (“DS-14”),

wherein the mixture of isomerically-purified hydroxypropyl β-cyclodextrin molecules has an average degree of substitution of about 7.5 to about 8.5.

22 . The composition of claim 21 , wherein the mixture further comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”).

23 . The composition of claim 21 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”).

24 . The composition of claim 21 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with three hydroxypropyl groups (“DS-3”).

25 . The composition of claim 21 , wherein the mixture further comprises less than 0.05% unsubstituted beta-cyclodextrin (“DS-0”) and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group (“DS-1”).

26 . The composition of claim 21 , wherein the composition further comprises no more than 10 ppb of propylene glycol as measured by HPLC.

27 . The composition of claim 21 , wherein the composition comprises no more than 1 ppm propylene oxide.

28 . The composition of claim 21 , wherein the composition comprises between 0 and 10 ppm chloride.

29 . The composition of claim 21 , wherein at least 50% of the hydroxypropyl substitutions in the hydroxypropyl-β-cyclodextrin molecules are located at the 2-O-position of the hydroxypropyl-β-cyclodextrin molecules.

30 . The composition of claim 21 , wherein 0% to 20% of the hydroxypropyl-β-cyclodextrin subunits are substituted at the 6-O-position.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2026
From: PFEIFFER, STEVEN; MCMINN, DUSTIN; BENKOVICS, GABOR
To: BEREN THERAPEUTICS P.B.C.
Reel/Frame 073450/0862 →